Oct. 26, 2012 | Vol. 11 No. 211 | Full Issue in PDF Format
View the entire issue.
The Senate Committee on Health, Education, Labor, & Pensions (HELP) is launching a probe of the compounding crisis, asking the Massachusetts pharmacy registrar to explain why New England Compounding Center (NECC) was allowed to operate as a large-scale drug manufacturer.
Slow remediation of GMP problems at Novartis’ Lincoln, Neb., OTC drug plant has dashed hopes for a pre-2013 return to production, company officials say.
Teva’s ascending-dose, extended-regimen oral contraceptive Quartette is effective at preventing pregnancy and has a comparable safety profile to other oral birth control pills, the company said.
Over the past quarter, Sanofi has reduced its R&D spending almost 11percent and has dropped two mid-stage projects acquired in its 2008 purchase of Fovea.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.